Nasal spray aims to fight COVID-19, but trial halted early

NCT ID NCT05541510

Terminated Disease control Sponsor: Advagene Biopharma Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a nasal spray called AD17002 in 180 adults with mild to moderate COVID-19. Participants received either a low dose, high dose, or placebo spray alongside standard care. The goal was to see if the spray speeds up recovery and improves symptoms. However, the trial was terminated early, so we have limited data on its effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AD17002 (LTh[αK]) intranasal spray
What this could lead to: If successful, this could provide a new treatment option for mild to moderate COVID-19 that boosts nasal immunity.
What could go wrong: The trial was terminated early, so results are limited. It is unclear if the treatment works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

RSA UGM

Yogyakarta, Special Region of Yogyakarta, 55281, Indonesia
RSDC Wisma Atlit

Kota Jkt Utara, DKI Jakarta, 14360, Indonesia
RSPI Sulianti Saroso

Kota Jkt Utara, DKI Jakarta, 14340, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.